Search clinical trials for: Lenalidomide placebo

Total 54637 results

ARCAGY/ GINECO GROUP

Completed

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse (REV)

Ovarian Cancer Recurrent

France
University Hospital, Bordeaux

Completed

Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma (REVALLO)

Multiple Myeloma

France
Hospital Universitari Vall d'Hebron Research Institute

Completed

Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus (ORDI-02)

Cutaneous Lupus

Spain
Medical University of Vienna

Unknown

Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

MALT Lymphoma

Austria
Florida Academic Dermatology Centers
Celgene Corporation

Unknown

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma (REvMM2009)

Cutaneous T Cell Lymphoma

United States
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma | Neurotoxicity | Therapy-related Toxicity

United States, Canada
Celgene

Completed

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
Celgene Corporation
Prologue Research International

Completed

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
University of South Carolina
U.S. Army Medical Research and Development Command

Completed

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

Seaweed Associated Changes in Healthy Subjects

United States
Dana-Farber Cancer Institute
Celgene

Active, not recruiting

A Study of Lenalidomide for Adult Histiocyte Disorders

Langerhans Cell Histiocytosis (LCH) | Histiocytoses Erdheim-chester Disease | Histiocytic Sarcoma (HS)

United States
Washington University School of Medicine
Celgene Corporation

Completed

Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

Hodgkin Disease

United States
University of Florida
Celgene Corporation

Terminated

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (UF-BMT-MRD-101)

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
Thomas Kipps
Celgene Corporation

Terminated

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Stanford University
Celgene Corporation

Terminated

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Leukemia | Relapsed Adult Acute Lymphocytic Leukemia

United States
Columbia University
Celgene Corporation

Completed

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Adult T Cell Leukemia/Lymphoma

United States
University of Arkansas

Completed

UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

Multiple Myeloma

United States
University Health Network, Toronto
Celgene Corporation

Completed

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

Canada
Oncology Specialists, S.C.
Celgene Corporation

Completed

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Prostate Cancer

United States
Georg Aue, M.D.
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma

United States
Celgene Corporation

Completed

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) (CRPS)

Complex Regional Pain Syndrome (RSD)

United States
Celgene Corporation
Prologue Research International

Terminated

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Prostate Cancer

United States
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Active, not recruiting

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

Critical Limb Ischemia

Poland
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Heart Failure

Poland
Shenyang Tenth People's Hospital
Beijing Tsinghua Changgeng Hospital

Not yet recruiting

Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC

Advanced HCC
Jiangxi Provincial People's Hopital

Not yet recruiting

Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis

Dermatomyositis

China
Sun Yat-sen University

Withdrawn

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Advanced Hepatocellular Carcinoma

China
Fundación Pública Andaluza para la gestión de la...

Unknown

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Mantle Cell Lymphoma

Spain
Celgene

Completed

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Neoplasms

United States
Celgene

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Peripheral T-cell Lymphoma | Adult T-cell Leukemia-Lymphoma

Japan
AHS Cancer Control Alberta
Alberta Cancer Foundation; Celgene Corporation

Completed

A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

T-cell Lymphoma

Canada
French National Agency for Research on AIDS and...
Celgene Corporation

Terminated

Lenalidomide in Kaposi Disease Associated With HIV Infection (LENAKAP)

HIV Infection Associated Kaposi Disease

France
Northwestern University
National Cancer Institute (NCI); Celgene

Active, not recruiting

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous... and other conditions

United States
University of Chicago

Active, not recruiting

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Multiple Myeloma

United States, Poland
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Spain, Italy, Austria
Institut de Cancérologie de la Loire
Celgene Corporation

Completed

Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia (RV-405 LAL)

Leukemia, Lymphoid | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

France
University of Leipzig
Mundipharma Pte Ltd.; Celgene Corporation; Amgen

Unknown

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Germany
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
University of Alabama at Birmingham

Recruiting

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Multiple Myeloma

United States
University Hospital, Toulouse
Celgene; Onyx Therapeutics, Inc.

Unknown

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction (IFM-CRd)

Multiple Myeloma

France
University of Pennsylvania

Completed

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
JW Pharmaceutical

Completed

Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients

Multiple Myeloma

Korea, Republic of, United States
New Mexico Cancer Care Alliance
Celgene Corporation

Terminated

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
PETHEMA Foundation
Celgene Corporation

Completed

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)

Multiple Myeloma

Spain
Celgene

Recruiting

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Lymphoma

Japan
IRCCS San Raffaele
Celgene

Completed

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma (RV-NHL-PI351)

Diffuse Large B-cell Lymphoma

Italy
UNC Lineberger Comprehensive Cancer Center
Celgene

Completed

Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction

Acute Myeloid Leukemia

United States
Mehrdad Abedi, MD
Celgene

Terminated

Phase I Study of Lenalidomide in Patients With Acute Leukemia

Acute Leukemia

United States

Search clinical trials for: Lenalidomide placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations